Mark Roschewski

30PUBLICATIONS
93CO-AUTHORS
Molecular targetsPredictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Haematological tumoursAutoimmunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (30)

|Mar 04, 2026
A phase 1 trial of romidepsin, azacitidine, dexamethasone, and lenalidomide in relapsed or refractory T-cell lymphoma.

Max J Gordon, Milos D Miljkovic, Paige Milhon

|Aug 13, 2025
Remission Assessment by Circulating Tumor DNA in Large B-Cell Lymphoma.

Mark Roschewski, David M Kurtz, Jason R Westin

|Jun 16, 2025
The anti-CD47 antibody magrolimab with obinutuzumab and venetoclax in relapsed or refractory indolent B-cell lymphomas.

Rahul Lakhotia, Christopher Melani, Stefania Pittaluga

|Apr 30, 2025
Glofitamab with Polatuzumab Vedotin in Refractory Burkitt's Lymphoma.

Anca Prica, Mark Roschewski, Peter Beale

|Sep 18, 2024
Magrolimab plus rituximab with or without chemotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma.

Joseph E Maakaron, Adam Asch, Leslie Popplewell

|Aug 30, 2024
Magrolimab plus rituximab in relapsed/refractory indolent non-Hodgkin lymphoma: 3-year follow-up of a phase 1/2 trial.

Amitkumar Mehta, Leslie Popplewell, Graham P Collins

Pageof 5

Frequent Collaborators

8 joint publications

Christopher Melani

6 joint publications

Rahul Lakhotia

5 joint publications

Wyndham H Wilson

5 joint publications

Elaine S Jaffe